Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review with pooled descriptive synthesis of mostly observational literature
PubMed 29216881 · doi:10.1186/s12958-017-0313-y
What was done
Authors searched PubMed, the Cochrane database, and reference lists through 2017 for English-language publications evaluating the risks and benefits of combined oral contraceptives (COCs) in women with polycystic ovary syndrome (PCOS). Collected data were pooled, summarized as medians with first and third quartiles, and analyzed using Wilcoxon signed-ranks tests for paired before-and-after samples.
What was found
The abstract reports no numerical values, effect sizes, medians, or exact p-values. Directionally, most COC preparations significantly decreased androgens and increased sex-hormone binding globulin (SHBG). Findings on carbohydrate metabolism were inconsistent but tended to show no additional risk or worsening of insulin sensitivity. For lipids, most COCs consistently increased total cholesterol, HDL cholesterol, and triglycerides.
Why it matters
This review synthesizes evidence on the metabolic and endocrine impacts of oral contraceptives in PCOS, indicating clear anti-androgenic benefits for hyperandrogenemic patients without clear evidence of worsened glycemic control.
Limits
The abstract provides no sample sizes, study counts, or quantitative metrics. Most included primary studies were observational, findings on carbohydrate metabolism remain inconsistent, and the clinical implications of the observed lipid elevations are undetermined.
Cited by
- supports Birth control pills stimulate sex hormone-binding globulin (SHBG) production, which binds circulating testosterone and helps relieve symptoms of PCOS.